Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical and evolutionary consequences of HIV adaptation to HLA: implications for vaccine and cure

Clinical and evolutionary consequences of HIV adaptation to HLA: implications for vaccine and cure Purpose of review The purpose of this review is to summarize recent advances in our understanding of HIV adaptation to human leukocyte antigen (HLA)-associated immune pressures and its relevance to HIV prevention and cure research. Recent findings Recent research has confirmed that HLA is a major driver of individual and population-level HIV evolution, that HIV strains are adapting to the immunogenetic profiles of the different human ethnic groups in which they circulate, and that HIV adaptation has substantial clinical and immunologic consequences. As such, adaptation represents a major challenge to HIV prevention and cure. At the same time, there are opportunities: Studies of HIV adaptation are revealing why certain HLA alleles are protective in some populations and not others; they are identifying immunogenic viral epitopes that harbor high mutational barriers to escape, and they may help illuminate novel, vaccine-relevant HIV epitopes in regions where circulating adaptation is extensive. Elucidation of HLA-driven adapted and nonadapted viral forms in different human populations and HIV subtypes also renders ‘personalized’ immunogen selection, as a component of HIV cure strategies, conceptually feasible. Summary Though adaptation represents a major challenge to HIV prevention and cure, achieving an in-depth understanding of this phenomenon can help move the design of such strategies forward. aCentre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico bMicrosoft Research, Seattle, Washington, USA cInstitute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Australia dCenter for Translational Immunology and Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA eFaculty of Health Sciences, Simon Fraser University, Burnaby fBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada Correspondence to Zabrina L. Brumme, PhD, Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada V5A 1S6. Tel: +1 778 782 8872; fax: +1 778 782 5927; e-mail: zbrumme@sfu.ca http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Clinical and evolutionary consequences of HIV adaptation to HLA: implications for vaccine and cure

Download PDF
11 pages

Loading next page...
 
/lp/wolters-kluwer-health/clinical-and-evolutionary-consequences-of-hiv-adaptation-to-hla-iSpJnpWr4F

References (141)

Publisher
Wolters Kluwer Health
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000541
Publisher site
See Article on Publisher Site

Abstract

Purpose of review The purpose of this review is to summarize recent advances in our understanding of HIV adaptation to human leukocyte antigen (HLA)-associated immune pressures and its relevance to HIV prevention and cure research. Recent findings Recent research has confirmed that HLA is a major driver of individual and population-level HIV evolution, that HIV strains are adapting to the immunogenetic profiles of the different human ethnic groups in which they circulate, and that HIV adaptation has substantial clinical and immunologic consequences. As such, adaptation represents a major challenge to HIV prevention and cure. At the same time, there are opportunities: Studies of HIV adaptation are revealing why certain HLA alleles are protective in some populations and not others; they are identifying immunogenic viral epitopes that harbor high mutational barriers to escape, and they may help illuminate novel, vaccine-relevant HIV epitopes in regions where circulating adaptation is extensive. Elucidation of HLA-driven adapted and nonadapted viral forms in different human populations and HIV subtypes also renders ‘personalized’ immunogen selection, as a component of HIV cure strategies, conceptually feasible. Summary Though adaptation represents a major challenge to HIV prevention and cure, achieving an in-depth understanding of this phenomenon can help move the design of such strategies forward. aCentre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico bMicrosoft Research, Seattle, Washington, USA cInstitute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Australia dCenter for Translational Immunology and Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA eFaculty of Health Sciences, Simon Fraser University, Burnaby fBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada Correspondence to Zabrina L. Brumme, PhD, Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada V5A 1S6. Tel: +1 778 782 8872; fax: +1 778 782 5927; e-mail: zbrumme@sfu.ca

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: May 1, 2019

There are no references for this article.